Standard chemo preferable to MDRs for Hodgkin's disease

Author：  

Publisher： Adis International

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1521, 2006-01, pp. : 15-15

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Chemotherapy with BEACOPP may challenge ABVD as the standard of care for patients with Hodgkin's disease

By  

Inpharma, Vol. 1, Iss. 1618, 2007-01 ,pp. : 6-6

Adis International

Access to resources Recommend Favorite

Interventional strategy preferable for unstable coronary artery disease

By  

Inpharma, Vol. 1, Iss. 1355, 2002-01 ,pp. : 15-15

Adis International

Access to resources Recommend Favorite

Thrombolysis with alteplase preferable to standard stroke therapy?

By  

Inpharma, Vol. 1, Iss. 1224, 2000-01 ,pp. : 6-6

Adis International

Access to resources Recommend Favorite

Standard chemo plus docetaxel does not compromise QOL

By  

Inpharma, Vol. 1, Iss. 1563, 2006-01 ,pp. : 16-16

Adis International

Access to resources Recommend Favorite

Gemcitabine increases efficacy of standard chemo for NSCLC

By  

Inpharma, Vol. 1, Iss. 1529, 2006-01 ,pp. : 8-8

Adis International

Access to resources Recommend Favorite